Trial Profile
A retrospective study of Ponatinib assessing prescribing patterns and outcomes in US Patients with chronic myeloid leukemia and acute lymphocytic leukemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Sep 2016
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Lymphoid leukaemia
- Focus Therapeutic Use
- 04 Feb 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology